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The pharmacological intervention  can play a crucial role in the reduction of craving and drinking and the maintenance of abstinence. This article
reviews pharmacotherapy for alcohol dependence with an emphasis on the naltrexone, dissulfiram and acamprosate. The opioid antagonist nal-
trexone lowers relapse rate, reduces drinking days and prolongs periods of abstinence. Acamprosate restores the normal activity of glutamate
and GABA systems. Disulfiram has been shown to be most effective for patients who believe in its efficacy and remain compliant with the treatment.
Ondansetron, has shown promise in the early-onset alcohol dependence but needs more extensive study. Topiramate (up to 300 mg per day) was
more efficacious than placebo in the treatment of alcohol dependence.
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syndrome as important adjuvant interventions for psychosocial treat-
ment. More recently, ondansetrom and topiramate have appeared as
promising therapeutical strategies, being in the approval phase.1 2 This
review of the literature will deal with currently-available PI for the
treatment of alcohol dependence, focusing on clinically-relevant issues
for professionals who deal with these patients.
Disulfiram
Disulfiram (DSF) was the first pharmacological intervention approved
by the FDA for the treatment of alcohol dependence. For the success of
treatment with DSF all patients should be engaged in some treatment
program. Supervised oral DSF is efficient, when incorporated to a
treatment which includes a community reinforcement approach, i.e.,
interventions developed in order to create new social skills, by means
of counseling, besides resocialization (e.g., social clubs) and recre-
ational activities which stimulate abstinence.3 4 It is important the
Introduction
Inadequate use of alcohol represents a serious worldwide public
health problem, what has stimulated innumerable investigations see-
king a better understanding of ethanol-related problems and their
modes of treatment. Knowing that half of the patients with alcohol
dependence syndrome relapse after a short detoxification period and
that studies in neurosciences are implying new neurotransmission
systems, such as those involved in mesocorticolimbic structures, in
their pathophysiology, the development of new pharmacological treat-
ment models has become an area of increasing worldwide interest.
Pharmacological Interventions.
During several years, the pharmacological interventions (PI) were
restricted to treatment of alcohol withdrawal syndrome (AWS) and to
the use of aversive drugs. In the last 10 years, naltrexone and acam-
prosate have been proposed for the treatment of alcohol dependence
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adoption of strategies to increase the compliance with treatment such
as: contingent social contracts - consisting of therapeutical agree-
ments between patients and the people involved in their treatment,
aiming that any of the family members supervise the administration of
the medication  behavioral monitoring of abstinence, besides some
form of positive reinforcement for abstinence. Treatment effectiveness
increases with these interventions. 
1. Mechanism of  action
DSF is an irreversible and nonspecific enzyme-inhibitory agent which
decomposes alcohol into the stage of acetaldehyde. When inhibiting the
enzyme acetaldehyde-dehydrogenase (ALDH), an accumulation of
acetaldehyde in the body will occur, leading to the ethanol-dissulfiram
reaction (figure1).
2. Contraindications
Among the contraindications, hepatic cirrhosis with portal hyperten-
sion may evolve with vomiting-induced visceral hemorrhage, during
the ethanol-disulfiram reaction. In pregnancy there is the risk of con-
genital anomalies. DSF may be used on patients with history of convul-
sions associated with alcohol withdrawal syndrome, provided it be
ruled out the presence of epilepsy. Other contraindication is organic
mental syndrome, due to the impairment of the patientsí capability of
understanding the risk of the ethanol-dissulfiram reaction. Patients
should be explained the toxic effects of DSF before its use, as to not
using it without their previous consent. Therefore, patients should
abstain completely from alcohol and have a full understanding of the
risks and principles of the treatment.
3. Adverse Effects
DSF is well-tolerated. Hepatitis is a rare adverse effect, which occurs
mainly after 2 months of treatment with this medication. Early detec-
tion of this clinical condition may be performed, inclu- ding their
mildest forms, by means of hepatic function tests. It is recommended
to monitor the hepatic function every three months in the maintenance
phase. In the first month of treatment, these lab exams may be per-
formed every two weeks.5
4. Clinical orientations
The habitual dose is 250 mg/day in a sole daily dose, after at least a 12-
hour abstinence interval. Patients may also benefit from 500 mg daily
doses. The recommended duration of treatment is one year. Other
alternative modes of administration include: use of low maintenance
doses during years or intermittent use on high-risk situations. The inhi-
bition of the enzyme ALDH may last for up to two weeks, after the sus-
pension of DSF.6 Patients should be oriented to avoid all alcohol
sources (e.g., vinegar).
Naltrexone
Naltrexone is an opiate antagonist, used as an adjuvant of psychosocial
interventions in outpatient treatment of alcoholism. In 1995, the FDA
approved naltrexone for the treatment of alcoholism. It is the first me-
dication to be approved, since the introduction of DSF. According to
Srisurapanont and Jarusuraisin,7 pre-clinical studies suggest that o-
pioid antagonists attenuate the pleasant effects of alcohol consump-
tion. Based on these animal studies, the efficacy and effectiveness of
naltrexone have been investigated in the treatment of alcohol depen-
dence.
1. Mechanism of action
Alcohol would stimulate indirectly the endogen opioid activity, by pro-
moting the release of endogen peptides (encephalins and endorphins),
in the synaptic cleft. The pleasant sensations of alcohol would be medi-
ated by the release of dopamine if the synaptic clefts of the nucleus
accumbens. Other mechanism proposed is the inhibitory acti- vity of
endogen peptides over the gabaergic inter-neurons situated in the ven-
tral tegmental area, which exert inhibitory effects on area A10
dopaminergic neurons. Naltrexone acts as a competitive antagonist on
opioid receptors. Therefore, the administration of opioid antagonists
would reduce the consumption of alcohol by means of the post-synap-
tic blocking of the and  opioid receptors  in the mesolimbic pathways.
2. Contraindications
The main contraindications to the use of naltrexone are acute and
chronic hepatic diseases. Among opioid users it is advisable to per-
form a test with naloxone to discard recent heroine use. The use of o-
pioid antagonists in heroine-dependent patients may trigger withdra-
wal syndrome symptoms, which start 5 minutes after the administra-
tion of the medication, lasting for approximately 48 hours. In these
patients a minimum period of seven days of abstinence is needed
before prescribing naltrexone chlorhiydrate. Among those treated with
methadone, a longer abstinence period is recommended: 10 to 14 days.
3. Adverse effects
The main adverse effect of naltrexone is nausea, which generally is
coincident with the plasmatic levels reached in a period of up to 90
minutes after the ingestion of the medication. Hepatotoxicity based on
the increase of hepatic transaminases (3 to 19 times the normal va-
lues) was observed on patients treated with high doses of naltrexone
(above 300 mg daily). In doses below 200 mg/day, no increase in hepa-
tic enzymes was found. However, it is important the monthly monito-
ring of bilirrubine values (total and fractions ) and of serum transam-
inases in the first three months, and afterwards every three months.
More frequent monitoring is indicated, when transaminases are high.
Naltrexone should be withdrawn when the rising of transaminases per-
sist, except if they are mild and attributed to alcohol consumption.
4. Clinical orientations
The recommended dose of naltrexone in the treatment of alcoholism is
50 mg/day. The therapeutic scheme consists of the prescription of 25
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mg/daily in the first week of treatment, aiming to decrease the inci-
dence and severity of the adverse effects. After this period, the dose
may be raised to 50 mg/daily. The clinical trials with naltrexone pro-
pose a 12-week treatment. According to O’Malley et al.,8 naltrexone
keep the reduced relapse rates up to the fifth month after its discon-
tinuation. Anton et al.9 have evidenced similar relapse rates among the
treatment groups, four months after discontinuation of naltrexone
chlorhydrate and placebo. Latt et al.10 found that the therapeutic
effects on relapse rates are stronger in the first 42 days of treatment.
Acamprosate
Acamprosate (calcium acetyl-homotaurinate) has been prescribed for
more than one decade in several countries and has proven efficient in
the treatment of alcohol dependence.11 Despite its approval for use in
the treatment of patients with Alcohol dependence syndrome in seve-
ral European and Latin-American countries, up to now it has not been
approved by the FDA for this indication.
1. Mechanisms of action
This medication inhibits the glutamatergic excitatory activity, acting,
probably, on a subclass of Glutamate (NMDA) receptors, especially
when there is hyperactivity of these receptors. Acamprosate has been
considered a partial coagonist of the NMDA receptor.12 There is evi-
dence that this medication reduces glutamate-induced calcium reup-
take on neurons, suppresses the conditioned responses to ethanol in
dependent animals, even on those with protracted abstinence, reduces
the aversive effects of alcohol withdrawal, inhibits the brain hyperex-
citability of glutamate and inhibits the c-fos gene expression.13 The
activity on the gabaergic system has been described, mainly involving
subcortical pathways. In an experimental study, Daoust et al.14 have
described that acamprosate improves the reuptake of GABA in the tha-
lamus and hypothalamus of inebriated rats. Stromberg et al.15 claim
that there are NMDA-type receptors in the nucleus accumbens which
receive stimuli from the amygdale, hippocampus, pre-frontal cortex
and ventral tegmental area. These receptors, thus, seem to modulate
the dopaminergic activity of the nucleus accumbens, reducing the
ethanol-related positive reinforcement.
2. Contraindications
Acamprosate has a good oral absorption, which is, however, impaired
by the concomitant ingestion of food. It is not metabolized, being com-
pletely eliminated by the kidneys. Besides, it has no protein link. All
these characteristics suggest that this medication has no preoccu-
pying interactions with other drugs. Patients with hepatic insufficiency
are able to receive acamprosate, as it suffers no pharmacokinetic
alteration. However, some authors proscribe the drug for patients with
hepatic insufficiency CHILD-PUGH C, but not for CHILD-PUGH A or B.
Pregnant women should not receive the medication, as there are no
reliable data about its safeness for the fetus.16
3. Adverse effects
In the clinical trials performed, there was no report of death attributed
to the medication.17 Acamprosate is well tolerated, however,
Tempesta18 reported that two patients had discontinued the treatment
due to the appearance of edema on inferior limbs after the drug star-
ted being used. Poldrugo11 reported that 1.6% of patients who received
acamprosate dropped out due to side-effects (nausea and vomiting in
one case and diarrhea in other one). In general, the adverse effects
reported are headache, gastrointestinal symptoms (abdominal pain,
nausea and vomiting) or dermatological (pruritus, maculo-papular
rash and blistering reactions. Sickness, mental confusion, somnolence
and alteration of libido were also reported. Five cases of overdose
associated with acamprosate were described (>43g), and all patients
recovered after gastric lavage. Monitoring of hypercalcemia is recom-
mended for patients with ëintoxicationí by this drug.19
4. Orientations
Acamprosate should be administered in alcohol-dependent patients
with more than 60 Kg, in three daily doses, being two capsules with 333
mg in the three periods of the day, always before meals. For patients
with less than 60 Kg, most of the studies suggest the administration of
lower doses, i.e., a capsule with 333 mg in the three periods of the day.
Maintenance time of the medication is variable. The clinical trials per-
formed used the drug for 6 to 12 months.20
Future Perspectives
Currently, two medications, topiramate and ondansetrom, have shown
promising in the treatment of alcohol-dependence. 
Topiramate is an antagonist of the Glutamate AMPA receptor, which
reduces the propriety of positive reinforcement related to the con-
sumption of ethanol. Johnson et al. (2003) have demonstrated, in one
double-blind, placebo-controlled study, the efficacy of topiramate in
alcohol-dependent patients, in terms of abstinence rates, reduction of
craving and decrease in the serum levels of serum gama-glutamil
transpeptidase (GGT). 
Ondansetron, a 5-HT3 antagonist, is a drug which has been proposed
for the treatment of subjects with early-onset alcohol dependence.
These patients present significant family history for alcohol depen-
dence and anti-social behavior. It is supposed that the neurochemical
substrate of these clinical characteristics is abnormalities of the sero-
toninergic system. Johnson et al. (2000) have evidenced decrease of
alcohol consumption among patients receiving 4g/kg of  ondansetron
along the 11 weeks of treatment.21
Conclusions
Acamprosate and naltrexone are important pharmacological
resources in the treatment of alcohol dependence syndrome. Under
certain paired conditions, disulfiram is also an efficient intevervention.
We highlighted promising results with topiramate and ondansetron
which should be replicated by further clinical trials. The pharmacolo-
gical research in this area remains always guided by the neurobiolo-
gical alterations triggered by the intense consumption of ethanol,
revealing new and promising breakthroughs. The pharmacological
treatment of chemical dependences as a whole should not be the main
therapeutical strategy, as innumerable other factors, besides the bio-
logical, compose these diseases, but should be thought as an impor-
tant medical tool for better approaching patients.
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